BeiGene Ltd. (NASDAQ:BGNE) Director Thomas Malley purchased 30,000 shares of BeiGene stock in a transaction dated Wednesday, November 23rd. The stock was bought at an average cost of $32.00 per share, for a total transaction of $960,000.00. Following the completion of the purchase, the director now directly owns 30,000 shares in the company, valued at approximately $960,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of BeiGene Ltd. (NASDAQ:BGNE) traded down 4.72% during midday trading on Monday, reaching $30.88. 113,072 shares of the company traded hands. The company’s 50 day moving average is $0.00 and its 200-day moving average is $0.00. BeiGene Ltd. has a 12 month low of $22.51 and a 12 month high of $37.89.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($1.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.30. Equities analysts anticipate that BeiGene Ltd. will post ($3.96) EPS for the current year.

Insider Buying and Selling by Quarter for BeiGene (NASDAQ:BGNE)

ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/28/beigene-ltd-bgne-director-buys-960000-00-in-stock.html.

A number of large investors have recently modified their holdings of BGNE. Credit Suisse AG boosted its stake in BeiGene by 9.1% in the third quarter. Credit Suisse AG now owns 12,000 shares of the company’s stock valued at $370,000 after buying an additional 1,000 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in BeiGene by 67.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 6,404 shares of the company’s stock valued at $191,000 after buying an additional 2,589 shares in the last quarter. BlackRock Inc. boosted its stake in BeiGene by 3,410.1% in the second quarter. BlackRock Inc. now owns 3,826 shares of the company’s stock valued at $114,000 after buying an additional 3,717 shares in the last quarter. Bank of Montreal Can purchased a new stake in BeiGene during the second quarter valued at about $191,000. Finally, Brown Advisory Inc. boosted its stake in BeiGene by 13.1% in the second quarter. Brown Advisory Inc. now owns 112,744 shares of the company’s stock valued at $3,360,000 after buying an additional 13,092 shares in the last quarter. 32.25% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have recently issued reports on BGNE. Zacks Investment Research raised shares of BeiGene from a “sell” rating to a “hold” rating in a research note on Tuesday, October 11th. Maxim Group set a $41.00 price target on shares of BeiGene and gave the company a “buy” rating in a research note on Saturday, October 8th. Finally, Cowen and Company reissued a “buy” rating on shares of BeiGene in a research note on Friday, October 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $40.00.

BeiGene Company Profile

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.

5 Day Chart for NASDAQ:BGNE

Receive News & Stock Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related stocks with our FREE daily email newsletter.